LIFECORE BIOMEDICAL, INC. \DE\

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Total Revenue $541.1m
$532.3m -1.63%
$524.2m -1.51%
$557.6m +6.36%
$590.4m +5.88%
$544.2m -7.83%
$185.8m -65.86%
$103.3m -44.42%
$128.3m +24.20%
$128.9m +0.47%
$128.9m 0.00%
Cost of Revenue $470.1m
$449.1m -4.48%
$445.9m -0.71%
$476.6m +6.88%
$515.4m +8.15%
$462.7m -10.22%
$135.4m -70.73%
$75.3m -44.41%
$86.4m +14.78%
$88.6m +2.50%
$88.6m 0.00%
Gross Profit $71.0m
$83.2m +17.23%
$78.3m -5.83%
$81.0m +3.40%
$75.0m -7.43%
$81.5m +8.65%
$50.4m -38.18%
$28.0m -44.44%
$41.9m +49.54%
$40.3m -3.71%
$40.3m 0.00%
Research and Development Expense $7.2m $9.5m $12.8m $11.5m $11.1m $10.2m $7.8m $8.7m $8.6m $8.3m $8.3m
Selling, General and Administrative Expense $49.5m $55.6m $52.0m $64.1m $72.2m $65.4m $46.1m $39.0m $40.5m $44.0m $44.0m
Amortization of Intangible Assets ($867k) $885k $969k $1.5m $2.0m $2.0m $1.4m $0 $0
Restructuring Costs $17.3m $17.6m $9.0m $4.2m
Operating Expenses $90.7m $67.7m $64.8m $75.5m $113.5m $95.0m $109.0m $49.8m $50.7m $140.9m
Operating Income (Loss) ($19.8m)
$15.5m +178.36%
$13.6m -12.37%
$5.5m -59.70%
($38.5m) -803.87%
($13.5m) +64.98%
($58.6m) -334.56%
($21.8m) +62.84%
($8.8m) +59.42%
($17.2m) -94.99%
($12.0m) +30.38%
Interest Expense $2.0m $17.4m $17.6m $21.8m
Interest Expense, Debt $22.2m $21.8m
Gain (Loss) Related to Litigation Settlement ($2.6m) $0
Other Nonoperating Income (Expense) $1.2m $900k $2.9m $1.6m ($4.4m) ($11.7m) $641k ($1.2m) ($3.1m) ($3k)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $18.9m $15.0m $16.4m $3.6m ($51.3m) ($40.5m) ($69.5m) ($63.9m) $9.5m ($38.7m) ($38.7m)
Current Income Tax Expense (Benefit) $2.4m $1.8m ($2.7m) $79k ($7.7m) $92k $379k $54k $27k $162k $43k
Income Tax Expense (Benefit) ($7.4m) $4.3m ($9.4m) $1.5m ($13.1m) ($7.8m) ($5.9m) $308k $183k $43k $43k
Net Income (Loss) Attributable to Parent ($11.6m)
$10.6m +190.97%
$24.8m +134.46%
$411k -98.34%
($38.2m) -9392.21%
($32.7m) +14.47%
($114.7m) -251.08%
($99.6m) +13.18%
$12.0m +112.07%
($38.7m) -422.29%
($44.4m) -14.57%
Net Income (Loss) Available to Common Stockholders, Basic $12.0m
($44.4m) -469.26%
($44.4m) 0.00%
Net Income (Loss) Attributable to Noncontrolling Interest $193k $87k $94k $0 $0 ($44.4m)
Preferred Stock Dividends, Income Statement Impact $0 $3.3m $3.3m
Earnings Per Share, Basic ($0.43) $0.39 $0.90 $0.01 ($1.31) ($1.12) ($3.90) ($3.32) $0.40 ($1.27) ($1.27)
Earnings Per Share, Diluted ($0.43) $0.38 $0.89 $0.01 ($1.31) ($1.12) ($3.90) ($3.32) $0.32 ($1.27) ($1.27)
Income (Loss) from Continuing Operations, Per Basic Share ($0) $0 $1 $0 ($1) ($1) ($2) ($2) $0 ($1)
Income (Loss) from Continuing Operations, Per Diluted Share ($0) $0 $1 $0 ($1) ($1) ($2) ($2) $0 ($1)
Weighted Average Number of Shares Outstanding, Basic 27.0m 27.3m 27.5m 28.4m 29.2m 29.3m 29.5m 30.0m 30.5m 34.8m 34.8m
Weighted Average Number of Shares Outstanding, Diluted 27.0m 27.7m 27.9m 28.6m 29.2m 29.3m 29.5m 30.0m 36.7m 34.8m 34.8m
Additional Financial Items
Capitalized Computer Software, Amortization $269k $414k $632k $900k $800k $1.1m $500k $500k $500k
Cost, Depreciation and Amortization $10.8m
Goodwill, Impairment Loss $0 $0 $0 $0 $7.9m $0 $20.0m $13.0m
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent $18.9m $15.0m $16.4m $3.6m $51.3m $40.5m $52.1m $63.9m $9.5m ($38.7m)
Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest $18.9m $15.0m $25.8m $2.1m ($38.2m) ($32.7m) ($63.5m) ($64.2m) $9.3m $38.7m
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest $18.9m $15.0m ($838k) ($1.7m) $0 $0 ($51.2m) ($35.3m) $2.7m $38.7m
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent $18.9m $15.0m $16.4m $3.6m $51.3m $40.5m $52.1m $63.9m $9.5m $0